Literature DB >> 28209261

The feasibility of transcatheter aortic valve implantation using the Edwards SAPIEN 3 for patients with severe bicuspid aortic stenosis.

Takahide Arai1, Thierry Lefèvre2, Thomas Hovasse1, Marie-Claude Morice1, Mauro Romano1, Hakim Benamer1, Philippe Garot1, Kentaro Hayashida3, Erik Bouvier1, Bernard Chevalier1.   

Abstract

BACKGROUND: There are currently only limited data focusing on transcatheter aortic valve implantation (TAVI) for bicuspid aortic valves (BAV) patients using the Edwards SAPIEN (Irvine, CA, USA) 3 (S3) valve. The aim of this study was to evaluate the feasibility and efficacy of TAVI using the S3 in patients with BAV.
METHODS: A total of 153 TAVI cases performed with the S3 were included. BAV was detected by multidetector computed tomography (MDCT) in 10 (7%) patients. The other patients had tricuspid aortic valves (TAV). The BAV and TAV groups were compared.
RESULTS: Patient age and logistic EuroSCORE were similar in the BAV and TAV groups. The calculated annulus average diameter (CAAD) by MDCT was significantly larger in the BAV group (26.5mm vs 23.7mm, p=0.036) as was the annular area by MDCT (562mm2 vs 446mm2, p=0.033). On the other hand, the valve diameter/CAAD ratio was significantly lower in the BAV group (1.01 vs 1.06, p=0.010) as was the annular area oversizing percentage (3% vs 11%, p=0.033). There were no significant differences between the two groups regarding the frequency of paravalvular aortic leakage (PVL) ≥2 (0% vs 6%, p=0.492) and the 30-day mortality rate (0% vs 1%, p=0.799).
CONCLUSIONS: Although TAVI for BAV tended to be carried out with a less oversized valve compared to TAVI for TAV, the frequency of post-procedural PVL ≥2 was similarly low in the two groups. TAVI using the S3 in patients with BAV seems to be feasible.
Copyright © 2017 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bicuspid aortic valve; SAPIEN 3; Severe symptomatic aortic stenosis; Transcatheter aortic valve implantation

Mesh:

Year:  2017        PMID: 28209261     DOI: 10.1016/j.jjcc.2016.12.009

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  5 in total

1.  Simulation study of transcatheter heart valve implantation in patients with stenotic bicuspid aortic valve.

Authors:  Salvatore Pasta; Stefano Cannata; Giovanni Gentile; Marzio Di Giuseppe; Federica Cosentino; Francesca Pasta; Valentina Agnese; Diego Bellavia; Giuseppe M Raffa; Michele Pilato; Caterina Gandolfo
Journal:  Med Biol Eng Comput       Date:  2020-02-06       Impact factor: 2.602

Review 2.  Comparing outcomes after transcatheter aortic valve replacement in patients with stenotic bicuspid and tricuspid aortic valve: A systematic review and meta-analysis.

Authors:  Napatt Kanjanahattakij; Benjamin Horn; Wasawat Vutthikraivit; Sylvia Marie Biso; Mary Rodriguez Ziccardi; Marvin Louis Roy Lu; Pattara Rattanawong
Journal:  Clin Cardiol       Date:  2018-07-18       Impact factor: 2.882

3.  Outcomes of transcatheter aortic valve replacement in bicuspid aortic valve stenosis.

Authors:  Tamunoinemi Bob-Manuel; Mark R Heckle; Ikechukwu A Ifedili; Jiajing Wang; Uzoma N Ibebuogu
Journal:  Ann Transl Med       Date:  2019-03

Review 4.  Expert Consensus on Sizing and Positioning of SAPIEN 3/Ultra in Bicuspid Aortic Valves.

Authors:  Daniel Blackman; Davide Gabbieri; Bruno García Del Blanco; Jörg Kempfert; Mika Laine; Julia Mascherbauer; Radoslaw Parma; Didier Tchétché
Journal:  Cardiol Ther       Date:  2021-06-03

5.  Patients With Bicuspid Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.

Authors:  Yi Zhang; Tian-Yuan Xiong; Yi-Ming Li; Yi-Jun Yao; Jing-Jing He; Hao-Ran Yang; Zhong-Kai Zhu; Fei Chen; Yuanweixiang Ou; Xi Wang; Qi Liu; Xi Li; Yi-Jian Li; Yan-Biao Liao; Fang-Yang Huang; Zhen-Gang Zhao; Qiao Li; Xin Wei; Yong Peng; Sen He; Jia-Fu Wei; Wen-Xia Zhou; Ming-Xia Zheng; Yun Bao; Xuan Zhou; Hong Tang; Wei Meng; Yuan Feng; Mao Chen
Journal:  Front Cardiovasc Med       Date:  2022-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.